| WB | 咨询技术 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 咨询技术 | Human,Mouse,Monkey |
| ICC | 1/50 - 1/250 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26 |
| Entrez GeneID | 3417 |
| clone | 7G8A1 |
| WB Predicted band size | 46.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human IDH1 (AA: 156-298) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于IDH1抗体的经典文献摘要概述：
---
1. **文献名称**：IDH1 mutations are detected in 6% of 540 AML cases and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years
**作者**：Paschka P et al. (2010)
**摘要**：该研究利用IDH1抗体进行免疫组化检测，发现IDH1突变在急性髓系白血病(AML)患者中的预后价值，证实抗体检测可有效识别突变蛋白，并与患者较差生存率相关。
---
2. **文献名称**：Monoclonal antibody IDH1m1 displays species-specific reactivity in immunohistochemical staining of mutant IDH1 in gliomas
**作者**：Capper D et al. (2010)
**摘要**：研究验证了IDH1m1单克隆抗体的特异性，证明其可精准识别IDH1 R132H突变体，但在非人类样本中存在物种限制性，为胶质瘤诊断提供了高灵敏度的检测工具。
---
3. **文献名称**：Sensitive detection of IDH1 mutations in gliomas using mutant-specific antibody
**作者**：Dubbink HJ et al. (2009)
**摘要**：通过对比测序法与IDH1突变特异性抗体的免疫组化结果，发现该抗体在胶质瘤样本中检测IDH1 R132H突变的灵敏度达97%，显著提升了临床诊断效率。
---
这些文献涵盖了IDH1抗体在肿瘤突变检测、预后评估及诊断技术优化中的关键应用。如需扩展，可补充抗体开发机制或治疗靶点相关研究。
IDH1 (Isocitrate Dehydrogenase 1) is a metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) in the cytoplasm, playing a critical role in cellular energy production and redox balance. Mutations in the IDH1 gene, particularly the R132H variant, are recurrently observed in various cancers, including gliomas, acute myeloid leukemia (AML), and chondrosarcoma. These mutations confer a neomorphic activity, enabling the enzyme to produce the oncometabolite D-2-hydroxyglutarate (2-HG), which accumulates and disrupts cellular processes by inhibiting α-KG-dependent enzymes involved in epigenetic regulation and cell differentiation.
IDH1 antibodies are essential tools for detecting mutant IDH1 protein in research and diagnostics. Immunohistochemistry (IHC) using mutation-specific antibodies (e.g., targeting R132H) enables rapid, cost-effective identification of IDH1-mutated tumors, aiding in tumor classification and prognosis. In glioblastoma, IDH1 mutation status is a key diagnostic marker, distinguishing primary from secondary tumors and correlating with better outcomes. Additionally, IDH1 antibodies are employed in Western blotting, immunofluorescence, and ELISA to study protein expression, localization, and functional alterations in disease models.
Therapeutic strategies targeting mutant IDH1. such as small-molecule inhibitors, are under clinical investigation. IDH1 antibodies also support drug development by validating target engagement and monitoring biomarker changes in preclinical and clinical studies.
×
